
Urothelial carcinoma (transitional carcinoma) begins in the urothelium, the tissue lining some areas of the urinary system. About 90% of bladder cancer cases and 7% of kidney cancer cases, including cancer of the renal pelvis and ureter, are caused by urothelial carcinoma. The symptoms of urothelial carcinoma-induced bladder and kidney cancers are comparable. Their prognoses are similar; these malignancies are easily treated when detected early but frequently return.
Urothelial carcinoma affects the bladder and kidneys in various ways. Bladder abnormal urothelial cells can move from the lining to deeper structures, potentially travelling to distant sites such as the liver, lungs, bones, fatty tissues, and lymph nodes. Low-grade bladder cancer is not likely to metastasise, whereas high-grade disease can be lethal and might recur. Urothelial carcinoma in the kidney may progress to develop tumours in the renal pelvis or ureter, which may then extend to other organs. Both diseases, if not treated, may lead to severe implications.
Transitional cell carcinoma (TCC), also known as urothelial carcinoma, needs to be treated early to enhance prognoses and prevent the cancer from spreading. If diagnosed early, TCC is often successfully treated with less invasive methods, such as localised or transurethral resection. Postponing therapy may make treatment more difficult and reduce survival by giving the cancer time to move to other parts of the body, such as the liver, lungs, or lymph nodes, or grow deeper into the bladder. Early treatment significantly enhances the outlook for individuals with TCC, controls symptoms, and prevents recurrence.
Symptoms of urothelial cancer may not be present at once. Usually, the first noticeable sign is blood in the urine. You should consult a healthcare provider if you notice any symptoms, including blood in the urine.
Causes
The exact aetiology of urothelial carcinoma in the kidneys and bladder is not known to medical scientists. They have found, however, a few common risk factors:
Risk Factors
Some risks of transitional cell carcinoma are mentioned below:
Turkey's recent advancements in managing transitional cell cancer (TCC) have revolved around new surgical and treatment approaches. Bacille Calmette-Guérin (BCG) immunotherapy is just one intravesical therapy that reduces recurrence, while transurethral resection of bladder tumors (TURBT) remains an essential non-muscle-invasive TCC treatment. Gemcitabine and platinum-based regimens are an in-demand therapy for muscle-invasive or metastatic TCC and are found to increase survival.
Although there is no guaranteed method to prevent Transitional Cell Carcinoma (TCC), the most important things you can do to lower your risk are to stop smoking, limit your exposure to certain chemicals at work, drink lots of water, and eat a diet high in fruits and vegetables.
Surgery is the primary treatment for localised TCC. This includes partial nephrectomy for kidney tumours and transurethral resection for bladder tumours. In certain situations, a radical cystectomy (removal of the bladder) or nephrectomy (removal of the kidney) may be necessary.
Chemotherapy: isfrequently used to eradicate any cancer cells that remain after surgery or for advanced TCC. Chemotherapy is administered intravenously or directly into the bladder for superficial bladder tumours.
Cost Start From USD 7420 - USD 30000Explore Options
Immunotherapy: Pembrolizumab and other immune checkpoint inhibitors are used more frequently, particularly for advanced or metastatic TCC, since they aid the immune system in recognising and combating cancer cells.
Cost Start From USD 7420 - USD 42500Explore Options
Radiation therapy is used to decrease tumours before surgery, particularly for bladder TCC, or to treat tumours in locations that are challenging for surgery to reach.
Targeted Therapy: Medications that attack cancer cells specifically based on genetic mutations or tumor-specific proteins are applied in targeted therapy for urothelial carcinoma. The medications can block the signals through which cancer cells grow and disseminate.
Cost Start From USD 7500 - USD 12000Explore Options
MediRehab (chain of Rehab centres - Part of MediGence) provides comprehensive rehabilitation services rehabilitation services to support patients through Teleconsulations and online therapy sessions.









Istanbul, Turkey
Memorial Atasehir Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:

Konya, Turkey
Medicana Konya Hospital located in Konya, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:

Istanbul, Turkey
Acibadem Bakirkoy Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Turkey is an excellent place for transitional cell carcinoma treatment because of its top-notch medical facilities, qualified oncologists, and best-in-class treatment facilities at reasonable prices. The nation has the latest technology-equipped state-of-the-art hospitals to facilitate effective diagnosis and treatment. Turkey’s hospitals are also internationally accredited, offering high-quality care.
Early-stage TCC kidney carcinoma may have over 90% survival, as the National Carcinoma Institute (NCI) reported. The survival rate may be 15% or below if the TCC has progressed past the bladder's inner lining or to other body parts.
The diagnosis of Transitional Cell Carcinoma, or TCC, is more prevalent among older individuals, particularly in Turkey, who are over the age of 55. It is more prevalent among men compared to women. With age, the risk increases due to factors such as prolonged exposure to carcinogens (such as nicotine and industrial chemicals) and the additive effects of long-standing renal or bladder diseases.
Since smoking is one of the substantial risk factors for bladder, kidney, and ureter cancers, it plays a significant role in developing Transitional Cell Carcinoma (TCC) in Turkey. Aromatic amines and various carcinogens present in tobacco smoke are absorbed into the bloodstream, filtered through the kidneys, and finally excreted in urine. These compounds can damage healthy urinary tract cells, causing mutations and the development of TCC. In Turkey, smoking is believed to increase an individual's risk of developing TCC by as much as three times for both genders. It is one of the country's leading preventable causes of TCC.
In Turkey, transitional cell carcinoma (TCC), especially of the bladder and ureters, can recur after treatment. TCC is a high-recurrence tumour, especially in superficial or early-stage cases, even after successful initial treatment, e.g., surgery or chemotherapy.
Regular follow-up with imaging, urine examination, and cystoscopy is mandatory to detect any recurrence at an early stage. Recurrence may be more aggressive and more challenging to manage in advanced cases. To manage the risk of recurrence, Turkish patients are advised to undergo therapy and monitoring on a routine basis.
In Turkey, radiation therapy is used to cure Transitional Cell Carcinoma (TCC) in cases where the tumour is incurable or advanced. It is also commonly used to cure bladder cancer, either alone or as a means to destroy cancer cells that remain even after surgery.
Radiation therapy can be combined with chemotherapy for better results. However, due to anatomical challenges, its use is limited to TCC, which aims to decrease symptoms, reduce tumours, and improve the overall quality of life.
Lifestyle and dietary changes can improve overall health and treatment outcomes for TCC patients in Turkey. Some recommendations include
Yes, you can get a second opinion on Transitional Cell Carcinoma treatment in Turkey through MediGence. With MediGence, you can connect with highly experienced professionals from top Turkish hospitals who can provide additional information regarding your diagnosis and treatment options. The platform facilitates easy access to professional help so you can make informed healthcare choices and receive the best care possible.
To find a certified cancer specialist, search MediGence’s website, which offers a list of top-class and internationally trained oncologists from Turkey's best hospitals. Through MediGence, you can search the profiles of specialists, check their credentials, reviews, and experience, and book online consultations. To get the best care for your condition, the website also assists you in finding the best hospitals and provides personalised assistance for your health requirements.